David A. Siegel Regenxbio Inc. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Regenxbio Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 70,100 shares of RGNX stock, worth $806,851. This represents 0.0% of its overall portfolio holdings.

Number of Shares

70,100

Previous 124,900 43.88%

Holding current value

$806,851

Previous $1.03 Million 34.05%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$7.46 - $9.89 $408,808 - $541,972	-54,800 Reduced 43.88%	70,100 $676,000
Q2 2025 Aug 14, 2025	SELL	$5.31 - $10.4 $382,851 - $749,840	-72,100 Reduced 36.6%	124,900 $1.03 Million
Q1 2025 May 15, 2025	BUY	$5.92 - $8.7 $100,640 - $147,900	17,000 Added 9.44%	197,000 $1.41 Million
Q4 2024 Feb 14, 2025	BUY	$7.23 - $11.56 $809,760 - $1.29 Million	112,000 Added 164.71%	180,000 $1.39 Million
Q3 2024 Nov 14, 2024	SELL	$10.49 - $14.39 $82,871 - $113,681	-7,900 Reduced 10.41%	68,000 $713,000

Q2 2024 Aug 14, 2024	BUY	$11.51 - $21.53 $215,237 - $402,611	18,700 Added 32.69%	75,900 $888,000
Q1 2024 May 15, 2024	BUY	$12.17 - $24.61 $542,782 - $1.1 Million	44,600 Added 353.97%	57,200 $1.21 Million
Q4 2023 Feb 14, 2024	BUY	$12.89 - $20.82 $162,414 - $262,332	12,600 New	12,600 $226,000
Q1 2023 May 15, 2023	SELL	$18.08 - $24.55 $45,199 - $61,375	-2,500 Reduced 19.08%	10,600 $200,000
Q4 2022 Feb 14, 2023	SELL	$20.4 - $24.73 $169,320 - $205,259	-8,300 Reduced 38.79%	13,100 $297,000
Q3 2022 Nov 14, 2022	BUY	$22.29 - $35.04 $91,389 - $143,664	4,100 Added 23.7%	21,400 $566,000
Q2 2022 Aug 15, 2022	BUY	$19.35 - $35.04 $79,335 - $143,664	4,100 Added 31.06%	17,300 $427,000
Q1 2022 May 16, 2022	BUY	$24.62 - $34.31 $324,984 - $452,892	13,200 New	13,200 $438,000
Q4 2021 Feb 14, 2022	SELL	$30.19 - $40.28 $1.6 Million - $2.13 Million	-53,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$29.09 - $45.68 $1.18 Million - $1.86 Million	40,700 Added 330.89%	53,000 $2.22 Million
Q2 2021 Aug 16, 2021	SELL	$32.46 - $40.48 $892,650 - $1.11 Million	-27,500 Reduced 69.1%	12,300 $478,000
Q1 2021 May 17, 2021	BUY	$33.61 - $49.95 $1.34 Million - $1.99 Million	39,800 New	39,800 $1.36 Million
Q3 2019 Nov 14, 2019	SELL	$31.84 - $50.88 $1.14 Million - $1.83 Million	-35,900 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$42.0 - $59.29 $2.26 Million - $3.19 Million	-53,800 Reduced 59.98%	35,900 $1.84 Million
Q1 2019 May 15, 2019	SELL	$40.82 - $62.45 $1.91 Million - $2.92 Million	-46,800 Reduced 34.29%	89,700 $5.14 Million
Q4 2018 Feb 14, 2019	BUY	$39.11 - $75.15 $109,508 - $210,420	2,800 Added 2.09%	136,500 $5.73 Million
Q3 2018 Nov 14, 2018	BUY	$65.0 - $82.15 $8.03 Million - $10.2 Million	123,600 Added 1223.76%	133,700 $10.1 Million
Q2 2018 Aug 14, 2018	SELL	$27.2 - $74.35 $228,480 - $624,540	-8,400 Reduced 45.41%	10,100 $725,000
Q1 2018 May 15, 2018	SELL	$24.05 - $37.5 $86,002 - $134,100	-3,576 Reduced 16.2%	18,500 $552,000
Q4 2017 Feb 14, 2018	BUY	$26.0 - $34.6 $573,976 - $763,829	22,076	22,076 $734,000

Others Institutions Holding RGNX

# of Institutions

189

Shares Held

44.3M

Call Options Held

138K

Put Options Held

117K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $498M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account